Pancreatic Surgery: Beyond the Traditional Limits

Abstract

Pancreatic cancer is one of the five leading causes of cancer death for both males and females in the western world. More than 85 % pancreatic tumors are of ductal origin but the incidence of cystic tumors such as intrapapillary mucinous tumors (IPMN) or mucinous cystic tumors (MCN) and other rare tumors is rising. Complete surgical resection of the tumor is the mainstay of any curative therapeutic approach, however, up to 40 % of patients with potentially resectable pancreatic cancer are not offered surgery. This is despite 5-year survival rates of up to 40 % or even higher in selected patients depending on tumor stage and histology. Standard procedures for pancreatic tumors include the Kausch-Whipple- or pylorus-preserving Whipple procedure, and the left lateral pancreatic resection (often with splenectomy), and usually include regional lymphadenectomy. More radical or extended pancreatic operations are becoming increasingly utilised however and we examine the data available for their role. These operations include major venous and arterial resection, multivisceral resections and surgery for metastatic disease, or palliative pancreatic resection. Portal vein resection for local infiltration with or without replacement graft is now well established and does not deleteriously affect perioperative morbidity or mortality. Arterial resection, however, though often technically feasible, has questionable oncologic impact, is not without risk and is usually reserved for isolated cases. The value of extended lymphadenectomy is frequently debated; the recent level I evidence demonstrates no advantage. Multivisceral resections, i.e. tumors, often in the tail of the pancreas, with invasion of the colon or stomach or other surrounding tissues, while associated with an increased morbidity and a longer hospital stay, do however show comparable mortality-and survival rates to those without such infiltration and therefore should be performed if technically feasible. Routine resection for metastatic disease however does not seem to show any advantage over palliative treatment but may be an option in selected patients with easily removable metastases. In conclusion pancreatic surgery beyond the traditional limits is established in tumors infiltration the venous system and may be a considered approach in selected patients with locally infiltrating pancreatic cancer or metastasis.

Metabolism addiction in pancreatic cancer

“…Thus, each year nearly 37 000 patients in the United States and >213 000 people worldwide die from this form of cancer. 1, 2 Despite extensive efforts and the considerable progress made toward improving its detection 3, 4, 5, 6 and survival rates over the past few decades, 7, 8, 9 the 5-year survival rate for pancreatic cancer has not changed significantly, increasing – according to data from surveillance, epidemiology and end results 2 – from 3% in 1975 to only 5.4% in 2005 (see other reviews Conroy et al, 10 Muller et al 11 and Poruk et al 12 ).…”

Portal Vein Resection During Pancreatectomy for Pancreatic Head Adenocarcinoma. Scope of Current Opinions and own Experiences

“…After pancreatoduodenectomy (PD) for pancreatic head adenocarcinoma, perioperative morbidity and long-term survival in patients with portal vein resection is similar to patients without need of portral vein resection (7)(8)(9)(10)21). In the case of tumor adherence or venous infiltration, a combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection (7)(8)(9)(10).…”

“…In the case of tumor adherence or venous infiltration, a combined resection of the pancreatic head and the vein should always be considered in the absence of other contraindications for resection (7)(8)(9)(10). The author believes that PVR should become a standard procedure during PD.…”

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

“…However, patients with a favourable tumour biology, albeit very rare, may be offered surgery [26]. The criteria to consider surgery include: good tumour control (>12 months) and very limited disease (single liver/lung metastasis).…”